The 5th International DAWN Summit in April 2014: Acting together to make person-centred diabetes care a reality.
DAWN2™ is featured at ADA's 73rd Scientific Session from 21st – 25th of June 2013 which will take place at McCormick Place Convention Centre, Chicago, Illinois.
DAWN2™ will be present during the 49th Annual EASD Meeting from 23rd – 27th of September 2013 which will take place at The Fira de Barcelona’s Gran Via exhibition Centre in Barcelona, Spain.
DAWN2™ will be present during IDF’s World Diabetes Congress from 2nd -6th of December 2013 which will take place at Melbourne Convention and Exhibition Centre in Melbourne, Australia.
The initial results of the DAWN2™ study were reviewed by representatives of key international and national diabetes organisations, clinicians, researchers, people with diabetes and their family members on the 2nd and 3rd of November 2012. These key stakeholders from all continents – who are committed to supporting the wider implementation of the study’s results – gathered in Copenhagen for a meeting hosted by the global partners of DAWN2™: the International Diabetes Federation (IDF), the International Alliance of Patients’ Organizations (IAPO), the Steno Diabetes Center and Novo Nordisk.
Members of the DAWN2™ International Publication Planning Committee (IPPC) presented the study’s initial results at the meeting, and workshops helped delegates to identify the most important messages from the study’s results and develop action plans for improving diabetes care in partnership with all relevant stakeholders.
Novo Nordisk was proud to announce the launch of DAWN2™ at the 2011 conference of the European Association for the Study of Diabetes in Lisbon, Portugal. Launching the study, Prof. Mark Peyrot (an internationally recognised professor of sociology) explained what makes DAWN2™ unique: it is the first study that aims to gain a 360° perspective on life with diabetes. This perspective is gained by engaging with key stakeholders across the spectrum of diabetes care, and the study’s findings will support Novo Nordisk and the DAWN2™ study partners in finding new ways to enable people with diabetes to be actively involved in managing their own health.